- Document Number:
20230248776
- Appl. No:
17/918093
- Application Filed:
October 08, 2021
- Abstract:
The present invention relates to a method for differentiating mesenchymal stem cells into osteoblasts, a cell therapeutic agent for treating bone disease including osteoblasts differentiated by the method and a method for producing the same. In addition, the present invention relates to a method for treating bone disease, including the step of administering the osteoblasts obtained by the method to a patient with bone disease. The differentiation method according to the present invention can stably and rapidly differentiate mesenchymal stem cells into osteoblasts. The differentiated osteoblasts have excellent blood vessel-forming ability and excellent bone-forming ability. Accordingly, the method for differentiating stem cells into osteoblasts and the osteoblasts obtained by the method, according to the present invention, can be effectively used as a cell therapeutic agent or treatment method related to bone disease.
- Assignees:
CEFO Co., Ltd. (Seoul, KR)
- Claim:
1. A method for differentiating mesenchymal stem cells into osteoblasts, comprising the steps of: i) coating an air-permeable polymer membrane with surfactant bubbles; ii) inoculating mesenchymal stem cells into the bubbles of step i) at a density of 1×103 to 1×105 cells/cm2; iii) differentiating the mesenchymal stem cells of step ii) into osteoblasts in a differentiation medium; and iv) isolating and obtaining osteoblasts differentiated in step iii).
- Claim:
2. The method of claim 1, wherein the surfactant of step i) is a poloxamer.
- Claim:
3. The method of claim 1, wherein the bubbles of step i) are produced by comprising the step of: generating bubbles by adding a surfactant on the air-permeable polymer membrane and moving.
- Claim:
4. The method of claim 1, wherein the mesenchymal stem cells of step ii) are derived from any one or more selected from the group consisting of umbilical cord, umbilical cord blood, placenta, amniotic membrane, bone marrow, fat, hair follicle, tooth, pulp and skin dermis.
- Claim:
5. (canceled)
- Claim:
6. The method of claim 1, wherein the osteoblasts have higher expression levels of connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2) and collagen type 1A1 (COL1A1) than undifferentiated stem cells and mature osteocytes; higher expression levels of angiopoietin 1 (ANGPT1) and alkaline phosphatase (AP) than undifferentiated stem cells; and lower expression levels of osterix (OSX), osteocalcin (OCN) and osteopontin (OPN) than mature osteocytes.
- Claim:
7. The method of claim 1, wherein the osteoblasts have a lower expression level of Ki-67 than undifferentiated stem cells.
- Claim:
8. A cell therapeutic agent for treating bone disease, comprising osteoblasts obtained by the method of claim 1.
- Claim:
9. The cell therapeutic agent of claim 8, wherein the osteoblasts have higher expression levels of connexin 43 (CX43), Runt-related transcription factor 2 (RUNX2) and collagen type 1A1 (COL1A1) than undifferentiated stem cells and mature osteocytes; higher expression levels of angiopoietin 1 (ANGPT1) and alkaline phosphatase (AP) than undifferentiated stem cells; and lower expression levels of osterix (OSX), osteocalcin (OCN) and osteopontin (OPN) than mature osteocytes.
- Claim:
10. The cell therapeutic agent of claim 8, wherein the osteoblasts have a lower expression level of Ki-67 than undifferentiated stem cells.
- Claim:
11. The cell therapeutic agent of claim 8, wherein the bone disease is any one or more selected from the group consisting of fracture, femoral head bone necrosis, spinal union, delayed union or nonunion, osteoporosis, osteonecrosis, pseudoarthrosis, Paget's disease and osteodystrophy.
- Claim:
12. A method for treating bone disease, comprising the step of: administering osteoblasts obtained by the method of claim 1 to a patient with bone disease.
- Current International Class:
61; 61
- Accession Number:
edspap.20230248776
Processing Request
No Comments.